Ironwood(IRWD) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, LINZESS U.S. net sales reached $865 million, with an 11% demand growth and 8% new-to-brand volume growth year-over-year [5][6] - The company reported a total revenue of $296 million for 2025, with GAAP net income of $24 million and Adjusted EBITDA of $138 million [19][21] - The company ended 2025 with $250 million in cash and cash equivalents, positioning itself well for 2026 [7][22] Business Line Data and Key Metrics Changes - LINZESS maintained its prescription market leadership for IBS-C and chronic constipation, achieving approximately 45% market share and surpassing 5.7 million unique patients treated since launch [11][12] - In Q4 2025, LINZESS U.S. net sales decreased by 27% year-over-year, primarily due to net price erosion, despite a 13% prescription demand growth [19][20] - The company expects LINZESS to return to blockbuster status in 2026, projecting U.S. net sales of over $1.1 billion, driven by improved net pricing and low single-digit prescription demand growth [7][23] Market Data and Key Metrics Changes - The company anticipates a more than 30% increase in LINZESS U.S. net sales in 2026 due to the elimination of the inflationary component of statutory required rebates [13][14] - The market for LINZESS remains strong, with over 40 million addressable patients in the U.S. and significant unmet needs in the IBS-C treatment space [11][12] Company Strategy and Development Direction - The company aims to maximize LINZESS and advance apraglutide, with clear priorities for 2026 including disciplined expense management and debt reduction [8][23] - The company plans to initiate the STARS-2 confirmatory Phase III trial for apraglutide in Q2 2026, with expectations of supporting an NDA submission by the end of 2029 [16][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercial opportunity for apraglutide, citing strong efficacy and tolerability data, and the potential to redefine the standard of care for short bowel syndrome [9][10] - The company is optimistic about the future of LINZESS, expecting continued strong net sales and cash flows, despite not providing specific guidance for 2027 and beyond [41] Other Important Information - The company has taken steps to lower the LINZESS list price effective January 1, 2026, to enhance patient access amid evolving healthcare dynamics [6][12] - The company is focused on maximizing shareholder value while considering strategic alternatives, given its improved financial position [34] Q&A Session Summary Question: Details on STARS-2 trial learnings and enrollment timeline - Management highlighted improvements in dosing administration and confidence in repeating the data from STARS-1, with a robust enrollment strategy for STARS-2 [27][30] Question: Update on strategic alternatives process - Management noted a significantly improved financial position and a clear path forward, while remaining open to alternatives that could enhance shareholder value [34] Question: Market opportunity for apraglutide amid potential generics - Management expressed strong conviction in apraglutide's clinical profile and market potential, even with anticipated competition from generics [56]